Amarantus Appoints Dr. Louis Kirby to Board of Advisors
March 31 2014 - 8:30AM
Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), a biotechnology
company focused on the discovery and development of novel
diagnostics and therapeutics related to neurodegeneration and
apoptosis, today appointed Dr. Louis Kirby to the Board of Advisors
to assist the Company in the development and commercialization of
the LymPro Test® for Alzheimer's disease. Dr. Kirby is a Board
certified neurologist who brings over 25 years of industry
experience to Amarantus, including work as principal investigator
on nearly 400 clinical trials, including drug and diagnostic trials
in Alzheimer's disease and other neurodegenerative conditions.
"I am extremely pleased to be joining Amarantus at this key
point in LymPro's development as we prepare to commercialize LymPro
in the 2nd half of 2014," said Dr. Kirby, Amarantus' newly
appointed corporate advisor. "The need for objective, non-invasive,
and reliable Alzheimer's biomarkers is at an all-time high. The
FDA's recent decision to approve a 3rd amyloid imaging agent for
adjunctive aid to the diagnosis of Alzheimer's disease demonstrates
an acute understanding of the value of incremental improvements in
the disease's diagnostic paradigm. We believe the LymPro Test® has
the potential to be significantly more valuable in terms of
specific information provided to the physician, while
simultaneously being drastically less expensive. This combination
could provide tremendous value to the healthcare system as we look
for new ways to care for patients, as well as facilitate the
development of therapeutic products that could ultimately alter the
course of the disease."
Dr. Kirby is a board certified neurologist, and is a specialist
in the development of drugs, medical devices, and laboratory
developed diagnostics, over the course of his career in the
pharmaceutical and medical device industry. He previously founded
Pivotal Research Centers, which became one of the nation's largest
free-standing private clinical research operations, before being
sold in 2005 to a public company. Dr. Kirby currently consults for
various biotechnology and large pharmaceutical companies. Dr. Kirby
previously worked as Chief Medical Officer at Provista Life
Sciences developing blood based biomarkers for breast cancer and
Alzheimer's disease. Dr. Kirby also previously served as Director
and co-Chair at the Critical Path Institute, working with
Alzheimer's and Parkinson's biomarkers in the regulatory arena,
working as a liaison between academia, industry and the FDA/EMA
(EMEA) where he assembled international expert panels and managed
their deliberations. Currently, Dr. Kirby is co-founder of
ZettaScience (ZettaScience.com), a mission-based science
infrastructure company offering a global scientific data search
engine for researchers at universities, government and industry
that promotes deeper scientific collaboration on pressing global
challenges. Dr. Kirby sits on the Board of Directors of the
Southwest Autism Research and Resource Center (SARRC) and chairs
their Medical Research committee. Dr. Kirby is also an author,
writing science-based thrillers including Shadow of Eden, a medical
and political thriller that currently is an Amazon bestseller. Dr.
Kirby obtained his undergraduate degree in honors Liberal
Arts at University of Texas (Austin) and his medical degree
from the University of Texas (Galveston).
"We are extremely pleased to welcome Dr. Kirby to Amarantus as
we prepare to commercialize LymPro in the second half of 2014,"
said Gerald E. Commissiong, Amarantus' President & CEO. "Dr.
Kirby's experience in understanding how LymPro functions by
measuring a critical component of Alzheimer's disease biology will
be highly valuable as we introduce LymPro to pharmaceutical
companies and Key Opinion Leading physicians in the medical
community over the course of the next year. Dr. Kirby's ability to
communicate and educate the general population and mainstream media
on key issues in healthcare product development will also be highly
valuable, as it has become clear that the world is anxiously
awaiting a commercially available and accurate blood test as an aid
in identifying Alzheimer's disease. We believe Dr. Kirby will add
excellent insight into our development and marketing efforts as we
move forward."
About Amarantus
Amarantus is a biotechnology company developing treatments and
diagnostics for diseases associated with neurodegeneration and
protein misfolding-related apoptosis. The Company has licensed
Eltoprazine ("Eltoprazine"), a phase 2b ready indication for
Parkinson's Levodopa induced dyskinesia and Adult ADHD. The Company
has an exclusive worldwide license to the Lymphocyte Proliferation
test ("LymPro Test®") for Alzheimer's disease and owns the
intellectual property rights to a therapeutic protein known as
Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is
developing MANF-based products as treatments for brain disorders.
Amarantus is a Founding Member of the Coalition for Concussion
Treatment (#C4CT), a movement initiated in collaboration with
Brewer Sports International seeking to raise awareness of new
treatments in development for concussions and nervous-system
disorders. The Company also owns intellectual property for the
diagnosis of Parkinson's disease ("NuroPro") and the discovery of
neurotrophic factors ("PhenoGuard"). For further information please
visit www.Amarantus.com, or connect with the Company on Facebook,
LinkedIn, Twitter and Google+.
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our
business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are
forward-looking statements. These forward-looking statements
generally are identified by the words "believes," "project,"
"expects," "anticipates," "estimates," "intends," "strategy,"
"plan," "may," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are based on current expectations and assumptions that are subject
to risks and uncertainties which may cause actual results to differ
materially from the forward-looking statements. Our ability to
predict results or the actual effect of future plans or strategies
is inherently uncertain. Factors which could have a material
adverse effect on our operations and future prospects on a
consolidated basis include, but are not limited to: changes in
economic conditions, legislative/regulatory changes, availability
of capital, interest rates, competition, and generally accepted
accounting principles. These risks and uncertainties should also be
considered in evaluating forward-looking statements and undue
reliance should not be placed on such statements.
CONTACT: Investor/Media Contacts
Aimee Boutcher, Director of Investor Relations
Amarantus Bioscience Holdings, Inc.
408-737-2734 x 101
ir@amarantus.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2023 to Apr 2024